echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Aging Cell: Tumor suppressor miR-34c as a new target for AD therapy

    Aging Cell: Tumor suppressor miR-34c as a new target for AD therapy

    • Last Update: 2022-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Epidemiological studies have shown that there is a negative correlation between Alzheimer's disease (AD) and cancer.


    1miR-34c is regulated by ROC-JNK-p53 and is associated with AD pathology

    The present study firstly determined the increased expression level of miR-34c in vivo (SAMP8 mouse model-aging accelerated model) and in vitro (H2O2-stimulated oxidative stress neurons and Aβ42-stimulated AD cell model)


    2miR-34c targets SYT1

    The target genes of miR-34c were predicted by bioinformatics analysis and validated


    3 Serum miR-34c levels increased in patients with mild cognitive impairment (aMCI)

    aMCI is a transitional stage between normal aging and dementia and represents an early stage of AD


    Figure.


    AD is an aging-related disease.


    Compilation Author: Peter Pan (Brainnews creative team)

    Reviewer: Victoria, Simon (Brainnews editorial office)

    references:

    Shi Z, Zhang K, Zhou H, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.